We have examined the hypothesis that TNF may play a pathogenetically important role in the hemolytic uremic syndrome. Specifically, we considered the possibility that shigatoxin, which eventuates this syndrome, might induce TNF biosynthesis, and/or that TNF and shigatoxin might sensitize animals, each to the toxic effects of the other agent. Shigatoxin was found to sensitize mice to the lethal effect of LPS and to the lethal effect of TNF. On the other hand, pretreatment of animals with either TNF or LPS did not noticeably sensitize mice to the lethal effect of shigatoxin. Intraperitoneal injections of shigatoxin did not induce the production of detectable quantities of TNF in the plasma of mice. When shigatoxin was injected into transgenic mice bearing a chloramphenicol acetyltransferase (CAT) reporter gene that indicates TNF synthesis, CAT activity was induced within the kidney, but not in other tissues. We therefore conclude that shigatoxin acts to induce TNF synthesis within the kidney, and at the same time increases renal sensitivity to the toxic effects of TNF. While this mouse model does not reproduce the hemolytic uremic syndrome as it occurs in humans, it does suggest that local synthesis of TNF within the kidney may contribute to renal injury induced by shigatoxin. (J. Clin. Invest. 1993Invest. . 92:2110Invest. -2116 
Introduction
Hemolytic uremic syndrome, a leading cause of acute renal failure in childhood, is associated with infection by Shigella dysenteriae serotype I and by enterohemorrhagic Escherichia coli. The virulence of these organisms has been linked to the production ofexotoxins (shiga-like toxins [SLTs] '). There are two major SLTs: E. coli SLT-I is essentially identical to shigatoxin made by S. dysenteriae serotype I, while E. coli SLT-II is less closely related. Shigatoxins (also called verotoxins) have been shown to cause renal tubular damage in animal models ( 1) . The pathologic changes produced do not precisely mimic those seen in human hemolytic uremic syndrome, perhaps because the shigatoxin receptor (Gb3) is not present on murine or lapine glomerular cells (2) .
The mechanism ofaction ofshigatoxin is clear. The toxin is a heterodimer, and acts as an inhibitor of protein synthesis, enzymatically modifying the translational machinery of the host cell (3) . However, the precise contribution of shigatoxinmediated inhibition of protein synthesis to the development of hemolytic uremic syndrome remains mysterious. Inhibition of protein synthesis is not, by itself, entirely consistent with the pathologic changes that are observed. The fibrin deposition and coagulopathy that characterize hemolytic uremic syndrome are reminiscent of the changes that occur in systemic sepsis, in which cytokines, notably TNF, play a prominent role (4, 5) . Some recently published data suggest the possibility ofcooperation between shigatoxin and TNF in producing the pathologic changes observed in hemolytic uremic syndrome (6) (7) (8) . There may be either local or systemic induction ofTNF synthesis by shigatoxin. Alternatively, TNF synthesis might be evoked in response to LPS, admitted from the gastrointestinal tract in the course ofthe hemorrhagic colitis that typically precedes hemolytic uremic syndrome. In either case, TNF might act in conjunction with shigatoxin to cause renal damage.
To study the events that take place after the entry of shigatoxins into the systemic circulation, we made use of a novel approach to the analysis of TNF biosynthesis and action. A chloramphenicol acetyltransferase (CAT) reporter ofTNF production, present in transgenic animals, was used to determine the site(s) ofTNF synthesis after shigatoxin (SLT-I) injection.
Methods
Mice. Animals used in these studies were of two types. C3H/HeN mice, obtained from Charles River Labs. (Wilmington, MA), were between 30 and 60 d ofage. C3H/HeJ mice, obtained from The Jackson Laboratory (Bar Harbor, ME), were of the same age range. Transgenic mice, bearing the CATTNF reporter construct (9) on a predominantly BALB/c background, were 30-75 d of age. The reporter construct contains the TNF promoter, 5'-untranslated region, and 3'-untranslated region, flanking a CAT coding sequence in the expected positions. It effectively mimicks the behavior of the TNF gene itself (9, 10) .
Animals were maintained in the University of Texas Southwestern Medical Center Animal Resource Center, and were fed ad libitum. They were injected with shigatoxin, TNF, LPS, or saline as indicated by an intraperitoneal route. Animals were weighed daily thereafter, and either scored for survival, or killed for histological and enzymatic analy- Tables I and II were each performed on one occasion, using five animals per group. Mouse TNF produced in E. colt was obtained from Genentech (S. San Francisco, CA). It had a specific activity of 2 x I07 U / mg protein, and contained < 1 ng LPS/mg protein.
Shigatoxin was prepared as previously described ( 11) . It was assayed for LPS content by a calorimetric Limulus amoebacyte lysate test ( 12) in the laboratory ofDr. Eric Hansen (UT Southwestern Medical Center), and found to contain 16 ng LPS/,gg of shigatoxin protein.
LPS ofE. coli strain 01 55:B8 was obtained from Difco Laboratories (Detroit, MI) and dissolved in normal saline for use in these studies.
TNF bioassay was performed using L929 cells as the target for cytotoxicity, as previously described ( 13) . The assay was sufficiently sensitive to detect TNF at a 10-pM concentration.
Tissues from transgenic mice were homogenized in 0.25 M Tris, pH 7.8, and frozen and thawed once to prepare a lysate for CAT assay. The soluble fraction ofthe lysate was heated to 650C and centrifuged before assay, as previously described (10) . The thin-layer chromatography technique ofGorman et al. ( 14) was used to determine CAT activity. A CAT standard was obtained from 5 Prime-3 Prime, Inc. (Boulder, CO). Incubation time with the substrate was 4 h.
Kidneys and colon were fixed in 10% neutral buffered formalin, processed in a standard manner, and stained with hematoxylin, eosin, and periodic acid-Schiff stains before microscopic examination.
Results
To assess the sensitivity to LPS and to shigatoxin ofthe population of mice used in these studies, dose-lethality curves were generated by injecting varying doses of each agent (Table I) . Mice were weighed daily after injection of LPS or shigatoxin, and scored for survival as well. Animals that died were examined histopathologically, as were survivors, which were killed for this purpose 4 d after injection of LPS or shigatoxin.
From these initial studies, it was concluded that the mean lethal dose (MLD) of LPS was between 300 and 500 ,gg. The MLD ofshigatoxin was between 0.3 and 0.7 ,g. Each agent was capable of causing renal injury, which was apparent at a lightmicroscopic level. Morphologic changes were limited to the renal tubules. The glomeruli appeared no different from the controls, and microvascular thrombosis was absent. The colon was unremarkable in all animals (not shown). The pattern of tubular injury differed between animals treated with LPS and animals treated with shigatoxin. In the former, the distal (and to a lesser extent, the proximal) renal tubular cells focally displayed increased cytoplasmic eosinophila and nuclear pyknosis without karyorrhexis ( Fig. 1 ). There was sloughing of some epithelial cells into the lumen. In shigatoxin-treated mice the distal tubules displayed nuclear vesiculation progressing to karyorrhexis, along with cytoplasmic vacuolation and fragmentation ( Fig. 2) . Nuclear pyknosis was also present to a lesser degree. Damage also involved the medullary collecting tubules of more severely affected animals. The proximal tubules showed only minimal focal nuclear pyknosis. Pretreatment with shigatoxin sensitized mice to the lethal effect of LPS, but the converse (i.e., sensitization of mice to the (Table II) . The time interval required for sensitization by shigatoxin was investigated by challenging mice with LPS at various intervals after shigatoxin injection. Doses of LPS that were normally sublethal were sufficient to kill mice pretreated with shigatoxin, and the optimal sensitization interval was approximately 3 d (Table II) . Histologic changes in the distal tubules were similar to, but more severe than, those observed after administration of shigatoxin alone (Fig. 3) .
In view ofthe fact that TNF acts as a major mediator ofLPS actions, we sought to determine whether shigatoxin would sensitize mice to the lethal effect of this cytokine, just as it appeared to sensitize to the effect of LPS. Pretreatment of mice with a normally sublethal dose of shigatoxin (0.3 ,ug) followed 3 d later by injection of20 ,gg ofTNF resulted in the death ofall ofthe animals in the group ( 10/ 10). When the same TNF dose was injected into mice pretreated with normal saline, only three of nine animals died (P < 0.003). In the saline pretreatment groups histologic changes were limited to mild nuclear pyknosis ofdistal tubular epithelium in animals that died (Fig.  4) . The histologic changes witnessed with shigatoxin pretreatment (Fig. 5) were similar to but less severe than those observed with shigatoxin and LPS. shigatoxin exerts a specific effect on renal tissue by virtue ofthe distribution ofits receptor, and perhaps as a result ofpostreceptor constraints as well.
We have demonstrated that shigatoxin is able to induce the biosynthesis of TNF within the kidney, and that TNF contributes to the development of renal injury that ensues after shigatoxin injection. This conclusion is based on the following observations. (a) Shigatoxin strongly potentiates the nephrotoxic effect of LPS and ofTNF. However, these agents do not potentiate the nephrotoxic effect of shigatoxin, and; (b) a reporter transgene indicates that shigatoxin is capable of inducing TNF synthesis within the kidney, but no other tissue.
Attempts to identify the biosynthesis of TNF itself in renal tissue through bioassay of organ culture supernatant were unsuccessful. We have previously noted that it is not possible to detect TNF synthesis elicited by LPS in the kidney ( 15) variance with the finding that, in mice, shigatoxin could sensitize to the lethal effect of LPS or TNF, but these latter two agents could not sensitize to the lethal effect ofshigatoxin. We are inclined to consider that the apparent discrepancy may be explained by a species difference, or by differences between the two experimental systems (e.g., the in vitro vs. in vivo administration of toxin). Overall, we favor the model depicted in Fig. 9 as an illustration ofthe roles played by LPS, shigatoxin, and TNF in the hemolytic uremic syndrome.
The participatory role of TNF in hemolytic uremic syndrome, as modeled by mice treated with shigatoxin, would immediately suggest therapeutic possibilities, in that antibodies directed against TNF, or soluble TNF receptors (17) , might mitigate the effects ofshigatoxin in human patients with hemolytic uremic syndrome. Since the inducing agent may persist for a period of several days, it is reasonable to consider that TNF induction may be a chronic process in hemolytic uremic syndrome; perhaps more so than in sepsis. Thus, the period of time during which effective intervention may be possible could be relatively long. by these studies. Presumably, these animals will be used in the identification of many other disease states in which TNF is a central participant.
